Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.
Parallel Pandemics From the Mind of Medicine (Podcast)
This is a podcast series accounting for the parallel pandemics of COVID-19 and clinician burnout, while introducing the story of one undocumented patient who helped to reveal the authentic feelings and values of his healthcare team. With historically high mortality rates in th...
WHO Resource: WHO recommends two new drugs to treat COVID-19
WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be.
The first drug, baricitinib, is strongly recommended for pat...
HHS Resource: COVID-19 Therapeutics Locator
The national map below displays public locations that have received shipments of U.S. Government-procured COVID-19 therapeutics under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) authority. The locations displayed in the locator have reported stock...
WHO Resource: WHO Therapeutics and COVID-19: living guideline
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via ...
FDA Resource: Paxlovid received EUA approval from the FDA
December 22, 2021, the FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years o...
FDA Resource: Molnupiravir received EUA approval from the FDA
The FDA has granted molnupiravir emergency use authorization (EUA) to treat mild to moderate COVID-19 in adults at high risk of severe illness. High risk people include adults aged 65 and over and people with certain medical conditions. The FDA also states that molnupiravir sh...